Results 71 to 80 of about 1,716,389 (207)

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.

open access: yesPLoS Pathogens, 2015
There are currently huge efforts by the World Health Organization and partners to complete global polio eradication. With the significant decline in poliomyelitis cases due to wild poliovirus in recent years, rare cases related to the use of live ...
Glynis Dunn   +5 more
doaj   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

open access: yesEuropean Journal of Haematology, Volume 116, Issue 4, Page 336-349, April 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot   +3 more
wiley   +1 more source

Polio control after certification: major issues outstanding

open access: yesBulletin of the World Health Organization, 2004
Now that the global eradication of wild poliovirus is almost within sight, planning for the post-certification era is becoming a priority issue. It is agreed that a stockpile of appropriate polio vaccines will need to be established, and a surveillance ...
Fine Paul E.M.   +2 more
doaj  

Determination of Factors Affecting Bivalent (Type 1 and 3) Stability of Oral Poliomyelitis Vaccine

open access: yesMedical Laboratory Journal, 2020
Background and objectives: After using of trivalent oral poliovirus vaccine (OPV) for a long time in Iran, in recent years, due to the eradication of type 2 of poliovirus, a bivalent vaccine containing types 1 and 3 is used.
Sina Soleimani
doaj  

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

open access: yesAdvanced Functional Materials, Volume 36, Issue 26, 30 March 2026.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras   +6 more
wiley   +1 more source

Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization [PDF]

open access: yes, 2020
Enormous progress has been made in global efforts to eradicate poliovirus, using live-attenuated Sabin oral poliovirus vaccine (OPV). However, as the incidence of disease due to wild poliovirus has declined, vaccine-derived poliovirus (VDPV) has emerged ...
Wei, Ling   +16 more
core   +1 more source

Past and Present Vaccinations in Sweden

open access: yes
Acta Paediatrica, EarlyView.
Sven Arne Silfverdal
wiley   +1 more source

Bee products as alternatives in the treatment of viral infections

open access: yesJournal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba   +3 more
wiley   +1 more source

Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention

open access: yesMedComm, Volume 7, Issue 1, January 2026.
The review manuscript examines the molecular pathogenesis, screening, prevention advances, and evolving targeted therapies in breast cancer. It highlights the integration of AI and multiomics for precision prevention and personalized treatment, pointing toward future directions in equitable cancer care.
Huijun Lei   +7 more
wiley   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

open access: yesMedicine Bulletin, Volume 2, Issue 1, Page 61-93, January 2026.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

Home - About - Disclaimer - Privacy